Source: Eur Respir J 2015; 46: 558-561



Rating:

Share or cite this content

Citations should be made in the following way:
Guerra Lorenzo, Favia Maria, Castellani Stefano, Barbuti Giovanna, Montemurro Pasqualina, Diana Anna, Santostasi Teresa, Polizzi Angela M., Mariggiò Maria A., Reshkin Stephan J., Manca Antonio, Casavola Valeria, Conese Massimo. Antibiotic therapy affects functional behaviour in cystic fibrosis blood mononuclear cells. Eur Respir J 2015; 46: 558-561

Member's Comments

No comment yet.

Related content which might interest you: Standard therapy increases the sensitivity of peripheral blood lymphocytes to glucocorticoids in cystic fibrosis but not in severe asthma Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011 Increased priming of blood neutrophils in children with clinically stable cystic fibrosis Source: Eur Respir J 2002; 20: Suppl. 38, 341s Year: 2002 Decreased mitochondrial complex I activity in blood lymphocytes of patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 Predicting prognosis of lung function decline in IPF using gene expression in peripheral blood mononuclear cells Source: International Congress 2017 – Current molecular and genetic understanding of lung diseases Year: 2017 Spontaneous release of interferon by peripheral blood mononuclear cells (PBMC) in patients with cystic fibrosis (CF) Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects Year: 2007 Altered composition of Innate lymphoid cells in BAL and blood of adult patients with cystic fibrosis towards ILC1 Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis Year: 2020 Peripheral blood myeloid-derived suppressor cells reflect disease status in idiopathic pulmonary fibrosis Source: Eur Respir J 2016; 48: 1171-1183 Year: 2016 Effect of ultrafine particle matter on human peripheral blood mononuclear cells of chronic obstructive pulmonary disease patients: involvement of the inflammasome. Source: International Congress 2017 – From the bench: therapeutic approaches in COPD and emphysema Year: 2017 The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects Source: Eur Respir Rev, 30 (161) 210055; 10.1183/16000617.0055-2021 Year: 2021 Evaluation of neutrophils phagocytosis and killing in pulmonary cystic fibrosis patients Source: International Congress 2019 – Infection and inflammation in cystic fibrosis Year: 2019 Posaconazole in vitro action on peripheral blood mononuclear cells from sarcoidosis patients Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Distribution and characterisation of lung mast cells in cystic fibrosis Source: Annual Congress 2009 - Airway inflammation and host defence Year: 2009 Cytokine releasing mucosa-homing T cells are increased in peripheral blood of pulmonary fibrosis patients Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Treatment of COPD exacerbations is able to influence the mononuclear cells level of the peripheral blood Source: Annual Congress 2008 - Basic science in asthma and COPD II Year: 2008 Lung stem cells and therapy for cystic fibrosis Source: Eur Respir Monogr 2021; 91: 306-321 Year: 2021 Frequency and phenotypical alterations of unconventional T cells in cystic fibrosis Source: Virtual Congress 2021 – Adult cystic fibrosis Year: 2021 CXCR4+ granulocytes reflect fungal cystic fibrosis lung disease Source: Eur Respir J 2015; 46: 395-404 Year: 2015 Chronic Pseudomonas aeruginosa lung infection, but not CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis Source: Virtual Congress 2021 – Adult cystic fibrosis Year: 2021 Ultrastructure of cells lung tissue and peripheral blood during HIV-infection Source: Eur Respir J 2005; 26: Suppl. 49, 407s Year: 2005 In vitro responses of peripheral blood mononuclear cells in severe asthma patient treated with Mepolizumab Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies Year: 2020